CARB-X accelerates global antibacterial innovation by supporting the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our portfolio represents the world’s most scientifically diverse, early development pipeline of new antibiotics, vaccines, rapid diagnostics, and other products to prevent, diagnose and treat life-threatening bacterial infections.
470.2
$million
Invested
103
innovative
Projects
13
different
Countries
12
human clinical
TRIALS
2
available
DIAGNOSTICS
2
advanced development
FUNDING
The Challenge
Accelerate the development of novel antibiotics and other new approaches to address drug-resistant bacterial infections.
Learn More
“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”
— Tim Jinks, Head of Infectious Diseases Interventions, Wellcome. Watch this video on what CARB-X is doing to address the rise of drug-resistant bacteria.
Proud recipient of the
2020 Innovating for Impact Partnership Award
from the Global Health Technologies Coalition (GHTC)
Watch video
Funders
Alliance Partners
